← Leaderboards
Peter Sazani
Ercole Biotech, Inc.
$2,463,288
Attributed
$3,158,741
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2007–23$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,158,741 · 4
By mechanism
R44$1,390,906 · 1
R42$1,345,974 · 1
R43$222,710 · 1
R41$199,151 · 1
Top collaborators
- Zhihua Feng1 shared
Others in their field
Top investigators on “Rna Splicing”
- Rolf Apweiler · European Molecular Biology Laboratory$41,336,566
- Daniel H Geschwind · University Of California Los Angeles$31,650,067
- Stacey Gabriel · Massachusetts Institute Of Technology$30,450,662
- Brenton R Graveley · University Of Connecticut Sch Of Med/Dnt$30,235,936
- Adrian R Krainer · Cold Spring Harbor Laboratory$28,755,040
- George M Church · Harvard University (Medical School)$26,862,961
Research focus
Rna SplicingDesignProteinsIn VivoVariantUp-Regulation (Physiology)Pharmaceutical PreparationsSafetyResearch StudySignal TransductionArthritisRheumatoid ArthritisBaseBinding (Molecular Function)OligonucleotidesExonsMembraneCellsLeadEtanerceptMouse ModelMrna PrecursorBlood CirculationInflammatory
Grant awards (6)
Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD$1,390,906
R44 · FY2023 · NS · contact PI
Targeted Degradation of CAG Repeat Expanded Huntingtin mRNA, Associated with Huntington's Disease, Using Artificial Site-Specific RNA Endonucleases$222,710
R43 · FY2018 · NS · contact PI
Upregulation of soluble TNFR2 as treatment for Rheumatiod Arthritis$694,600
R42 · FY2009 · AR · contact PI
Upregulation of soluble TNFR2 as treatment for Rheumatiod Arthritis$650,934
R42 · FY2008 · AR · contact PI
Upregulation of soluble TNFR2 as treatment for Rheumatiod Arthritis$440
R42 · FY2008 · AR · contact PI
Upregulation of soluble TNFR2 as treatment for Rheumatoid Arthritis$199,151
R41 · FY2007 · AR · contact PI